i. Biochemical Endpoints - Power is based on paired t-tests comparing continuous measures of response between treatment and placebo. We assume 40 subjects will be available after allowing for a drop out rate of 20% from our original sample of 50 subjects. For the endpoint of leukotriene production by leukocytes, the power calculations suggested that we will have 80% power to detect a true within-subject difference of 0.8 of the within-subject SD between treatment and placebo with an α value of 0/05. On the basis of our previous studies, we assume a within-subject coefficient of variation (CV) of 13% for LTC4 generation. This will translate to an approximate detectable difference from 10.5% in these parameters.Using a paired two-sided t-test and prior mean(standard deviation) estimates for the placebo of .001464 ( .002268) and for the borage oil of .000289( .000709) , we would need 40subjects for 80-90% power at a 0.05 level of significance to detect a change in LTC4S transcript, protein, and enzymatic activity of 50% between placebo and borage arms.